Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs.

Pfizer Nears $7.3Billion Deal to Acquire Metsera's Weight-Loss Drug

Pfizer is in the final stages of a deal to purchase Metsera, offering $47.50 in cash per share and an additional $22.50 if specific performance targets are achieved, as reported by Financial Times. This would value Metsera at up to $7.3 billion, making it the largest acquisition of an experimental weight-loss treatment by a major pharmaceutical company.

The acquisition could be announced as early as Monday, pending any last-minute complications. The deal would provide Pfizer with an experimental drug, MET-097i, which could potentially compete in the development ...